Ocular Therapeutix, Inc. (OCUL) Stock Forecast
OCUL analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 12 analysts
- Price target
- $26.00 average of analyst targets
- Upside to target
- +278.5% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-0.36
- 52-week range
- $6.87 – $16.11
OCUL analyst ratings
12 analystsNumber of analysts at each rating.
OCUL price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
OCUL earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.35 | −$0.37 | −$0.30 | −$0.38 | +6.6% | 6 |
| Current fiscal year (2026) | −$1.44 | −$1.54 | −$1.18 | −$1.42 | −1.7% | 5 |
| Next fiscal year (2027) | −$1.48 | −$1.86 | −$1.09 | −$1.44 | −2.5% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
OCUL revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $14.3M | $13.4M | $16.0M | −1.7% | 12 |
| Current fiscal year (2026) | $52.8M | $50.8M | $56.2M | +1.7% | 12 |
| Next fiscal year (2027) | $102.0M | $57.5M | $183.0M | +93.1% | 12 |
OCUL EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
OCUL revenue: reported and forecast
OCUL EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.39 | −$0.35 | −$0.35 | −$0.35 | −$0.35 | −8.4% | 4 up · 0 down |
| Current fiscal year (2026) | −$1.55 | −$1.43 | −$1.43 | −$1.43 | −$1.44 | −7.0% | 3 up · 0 down |
| Next fiscal year (2027) | −$1.54 | −$1.45 | −$1.45 | −$1.45 | −$1.48 | −3.7% | 3 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
OCUL earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; OCUL beat in 3 of 12.
What analysts expect from OCUL
12 analysts cover Ocular Therapeutix; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $26.00, 278.5% above the latest close of $6.87. Analysts expect earnings of −$1.44 per share for 2026, −1.7% from a year earlier. For 2027 the average estimate is −$1.48 per share on revenue of $102.0 million. Ocular Therapeutix beat the EPS estimate in 3 of the last 12 quarters.
Related: OCUL income statement, OCUL key metrics, OCUL chart. See the OCUL stock overview for the latest quote and news.
OCUL forecast FAQ
What is Ocular Therapeutix's price target?
The average analyst price target for Ocular Therapeutix is $26.00, 278.5% above the latest close of $6.87.
Is Ocular Therapeutix a buy, hold or sell?
Of 12 analysts covering Ocular Therapeutix, 8 rate it a strong buy, 4 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Ocular Therapeutix's EPS forecast?
Analysts forecast −$1.44 per share for 2026 (range −$1.54 to −$1.18); for 2027 the estimate is −$1.48.
What is Ocular Therapeutix's revenue forecast?
The average revenue estimate for 2026 is $52.8 million, growth of 1.7%; for 2027 it is $102.0 million.
When does Ocular Therapeutix report earnings?
Ocular Therapeutix is expected to report results for the quarter ending September 30, 2026 on November 3, 2026; the EPS estimate is $-0.36.
Does Ocular Therapeutix usually beat earnings estimates?
Ocular Therapeutix reported EPS at or above the analyst estimate in 3 of the last 12 quarters.